Free Trial

Spyre Therapeutics (SYRE) News Today

Spyre Therapeutics logo
$14.93 +0.71 (+4.99%)
As of 04/24/2025 04:00 PM Eastern
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics (NASDAQ:SYRE) Trading Down 3.6% - Here's Why
Spyre Therapeutics (NASDAQ:SYRE) Trading Down 3.6% - What's Next?
Spyre Therapeutics, Inc. stock logo
Capital World Investors Invests $8.81 Million in Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Capital World Investors purchased a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 378,573 shares of the company's stock, valued at approx
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 6.3% - Still a Buy?
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Up 6.3% - What's Next?
Spyre Therapeutics, Inc. stock logo
B Group Inc. Buys Shares of 50,000 Spyre Therapeutics, Inc. (NASDAQ:SYRE)
B Group Inc. purchased a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 50,000 shares of the company's stock, valu
Spyre Therapeutics, Inc. stock logo
Geode Capital Management LLC Buys 75,081 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Geode Capital Management LLC raised its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 8.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 966,129 shares of the company's stock after purchasing an
Spyre Therapeutics, Inc. stock logo
Affinity Asset Advisors LLC Purchases 325,908 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Affinity Asset Advisors LLC increased its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 65.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 824,328 shares of the
Spyre Therapeutics, Inc. stock logo
Fmr LLC Grows Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Fmr LLC lifted its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 15.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,801,266 shares of the company's stock after buying an additional 1,177,385 sha
Spyre Therapeutics, Inc. stock logo
F M Investments LLC Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)
F M Investments LLC purchased a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 48,806 shares of the company's stock, valued at approximately $1,136,000. F M Investments LLC
Spyre Therapeutics, Inc. stock logo
Vanguard Group Inc. Buys 330,553 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Vanguard Group Inc. raised its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 13.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,846,473 shares of the company's stock after acqu
Spyre Therapeutics, Inc. stock logo
What is Leerink Partnrs' Estimate for SYRE Q1 Earnings?
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Spyre Therapeutics in a research note issued on Tuesday, April 8th. Leerink Partnrs analyst F. Khurshid anticipates that the company will post earnings per share of (
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics (NASDAQ:SYRE) Upgraded to "Strong-Buy" at Leerink Partnrs
Leerink Partnrs upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a research report on Tuesday.
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics (NASDAQ:SYRE) Now Covered by Leerink Partners
Leerink Partners assumed coverage on Spyre Therapeutics in a report on Tuesday. They set an "outperform" rating and a $45.00 price objective for the company.
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year Low - Here's What Happened
Spyre Therapeutics (NASDAQ:SYRE) Reaches New 12-Month Low - Here's Why
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Recommendation of "Buy" from Analysts
Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) have received a consensus recommendation of "Buy" from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has as
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Bought by Wellington Management Group LLP
Wellington Management Group LLP grew its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 6.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,604,508 shares of the company's stock after purchasing a
Spyre Therapeutics, Inc. stock logo
Schroder Investment Management Group Takes $2.56 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Schroder Investment Management Group bought a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 113,620 shares of the company's stock, valued at approximately $2,561,000. Schr
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock Holdings Lowered by Cinctive Capital Management LP
Cinctive Capital Management LP cut its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 68.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 19,567 shares of the company's stock after sellin
Spyre Therapeutics, Inc. stock logo
Pictet Asset Management Holding SA Buys 266,418 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Pictet Asset Management Holding SA lifted its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 32.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,092,124 shares of the company'
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics (NASDAQ:SYRE) Reaches New 52-Week Low - Time to Sell?
Spyre Therapeutics (NASDAQ:SYRE) Reaches New 52-Week Low - Should You Sell?
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 7.7% - Here's What Happened
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 7.7% - What's Next?
Spyre Therapeutics, Inc. stock logo
Swiss National Bank Buys 19,000 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Swiss National Bank grew its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 38.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 68,600 shares of the company's stock after purchasing an additional 19,000 shares
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - Here's Why
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - Here's What Happened
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics (NASDAQ:SYRE) Shares Up 5.2% - Still a Buy?
Spyre Therapeutics (NASDAQ:SYRE) Shares Up 5.2% - Here's Why
Spyre Therapeutics, Inc. stock logo
Natixis Advisors LLC Purchases Shares of 17,300 Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Natixis Advisors LLC purchased a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 17,300 shares of the company's stock, v
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year Low - Here's Why
Spyre Therapeutics (NASDAQ:SYRE) Reaches New 52-Week Low - Should You Sell?
Spyre Therapeutics, Inc. stock logo
EFG Asset Management North America Corp. Boosts Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)
EFG Asset Management North America Corp. raised its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 58.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 82,818 shares of the comp
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 6.4% - Here's What Happened
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 6.4% - What's Next?
Spyre Therapeutics, Inc. stock logo
Emerald Advisers LLC Acquires 254,222 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Emerald Advisers LLC grew its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 86.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 546,791 shares of the company's stock after purchasing an a
Spyre Therapeutics, Inc. stock logo
Charles Schwab Investment Management Inc. Has $8.84 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Charles Schwab Investment Management Inc. boosted its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 13.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 379,650 shar
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - What's Next?
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - Here's Why
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics (NASDAQ:SYRE) Coverage Initiated at Wolfe Research
Wolfe Research initiated coverage on Spyre Therapeutics in a research report on Tuesday. They set an "outperform" rating and a $27.00 target price for the company.
Spyre Therapeutics initiated with an Outperform at Wolfe Research
Spyre Therapeutics, Inc. stock logo
Victory Capital Management Inc. Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Victory Capital Management Inc. bought a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 268,076 shares of the company's stock, valued at approximately
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by Brokerages
Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) have earned a consensus recommendation of "Buy" from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - Should You Buy?
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - What's Next?
Spyre Therapeutics, Inc. stock logo
Candriam S.C.A. Has $5.76 Million Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Candriam S.C.A. boosted its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 135.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 247,591 shares of the company's stock after buying
Wedbush Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics (NASDAQ:SYRE) Shares Up 6.6% After Earnings Beat
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 6.6% Following Earnings Beat
Spyre Therapeutics, Inc. stock logo
Spyre Therapeutics (NASDAQ:SYRE) Posts Earnings Results, Beats Expectations By $0.08 EPS
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.08.
Spyre Therapeutics files $500M mixed securities shelf
Get Spyre Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter.

SYRE Media Mentions By Week

SYRE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SYRE
News Sentiment

1.05

0.73

Average
Medical
News Sentiment

SYRE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SYRE Articles
This Week

5

4

SYRE Articles
Average Week

Get Spyre Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:SYRE) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners